Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580277 · ClinicalTrials.gov registry record · Phase 2
Tofacitinib For Treatment Of Chronic Pouchitis
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04580277: Clinical Trial Phase 2 study, sponsored by Cedars-Sinai Medical Center.
NCT04580277 is a Phase 2 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04580277, a Phase 2 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis
Primary Outcome
The proportion of subjects with clinical response at 8 weeks, defined as ≥2-point decrease in modified pouchitis disease activity index (mPDAI) with at least 1-point decrease in endoscopic subscore compared to the baseline.The mPDAI is a 0- 18 point scale of pouchitis disease severity, with higher scores corresponding to worse disease severity.
Interventions
- DRUG Tofacitinib 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 2 |
Why NCT04580277 stopped before completion
NCT04580277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib 10 mg is the first listed.
NCT04580277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04580277 about?
NCT04580277 is a clinical study titled "Tofacitinib For Treatment Of Chronic Pouchitis". A phase 2 pilot study to evaluate the effectiveness of tofacitinib in subjects with chronic pouchitis
What is the current status of trial NCT04580277?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-01-25. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT04580277?
The interventions under investigation include: Tofacitinib 10 mg (DRUG).
Who is sponsoring clinical trial NCT04580277?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04580277's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI